CARTEOLOL HYDROCHLORIDE (carteolol hydrochloride) by Bausch + Lomb is clinical pharmacology carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Approved for hypertension, glaucoma. First approved in 2000.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Carteolol Hydrochloride reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by…
Worked on CARTEOLOL HYDROCHLORIDE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.